Research advances in the application of microfluidic chip technology for rapid detection of antibiotic-resistant bacteria.

The escalating global burden of antimicrobial resistance (AMR) necessitates diagnostic strategies that can overcome the limitations of conventional culture-based methods, which often require several days to generate clinically actionable results. Such delays are associated with increased mortality, inappropriate antibiotic use, and continued transmission of resistant pathogens. In this context, microfluidic chip technology has emerged as a promising platform for rapid, miniaturized, and increasingly automated point-of-care diagnostics. Recent advances have enabled integrated lab-on-a-chip systems that combine bacterial isolation, phenotypic antimicrobial susceptibility testing, and genotypic resistance detection within closed and self-contained architectures, thereby reducing contamination risk and operator dependence. In addition, these platforms are increasingly capable of operating at single-cell resolution, allowing the detection of heteroresistance and resistant subpopulations that may be overlooked by conventional bulk assays. A major advantage of microfluidic systems is their ability to bridge phenotypic and genotypic diagnostics by enabling real-time monitoring of bacterial growth, metabolic activity, and morphological responses to antibiotics while simultaneously incorporating on-chip nucleic acid amplification for resistance gene detection. This integrated approach improves the interpretation of discrepancies between genetic determinants and functional resistance. Studies to date have demonstrated high sensitivity and specificity in complex clinical matrices, including blood, urine, and sputum, with turnaround times reduced from days to less than one hour in some applications. Furthermore, the integration of CRISPR-Cas systems, nanomaterial-enhanced biosensing, and machine learning has further improved analytical performance and data interpretation. Nevertheless, important translational challenges remain, including scalable manufacturing, regulatory standardization, and integration into routine clinical workflows. Future microfluidic platforms are expected to support multiplexed, intelligent antimicrobial susceptibility testing capable of simultaneous pathogen identification, resistance profiling, and therapeutic guidance, thereby advancing precision diagnostics for AMR management.